Outcomes of patients with the third or higher relapsed classical Hodgkin lymphoma: results from the German Hodgkin Study Group
Authors:
- 1 March 2019
- journal article
- letter
- Published by Elsevier in Annals of Oncology
- Vol. 30 (3) , 490-491
Abstract
No abstract availableFunding Information
- Bristol-Myers Squibb
- Celgene
- Amgen
- Meso Scale Diagnostics
- Merck
- Takeda Pharmaceuticals North America
- Novartis Pharma
This publication has 5 references indexed in Scilit:
- Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin LymphomaBlood, 2018
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 TrialJournal of Clinical Oncology, 2018
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin LymphomaJournal of Clinical Oncology, 2017
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trialThe Lancet Oncology, 2016
- Treatment of relapsed and refractory Hodgkin LymphomaSeminars in Hematology, 2016